Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients

被引:133
作者
Seong, J
Park, HC
Han, KH
Chon, CY
机构
[1] Yonsei Univ, Coll Med, Dept Radiat Oncol, Seodamun Ku, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Brain Korea Project Med Sci 21,Seodamun Ku, Seoul 120752, South Korea
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 55卷 / 02期
关键词
hepatocellular carcinoma; radiotherapy; survival; prognostic factor;
D O I
10.1016/S0360-3016(02)03929-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To analyze the treatment results and prognostic factors affecting survival in patients with unresectable hepatocellular carcinoma treated with local radiotherapy (RT). Methods and Materials: Between 1992 and 2000, 158 patients with unresectable hepatocellular carcinoma received local RT. Sixty-seven patients had an advanced UICC Stage III lesion and 91 patients had Stage IVA. The mean tumor size was 9.0 +/- 3.0 em, and liver cirrhosis was present in 142 patients. Local RT was combined with transarterial chemoembolization as primary treatment (107 patients) or as salvage after failure of repeated transarterial chemoembolization (51 patients). The mean radiation dose was 48.2 +/- 7.9 Gy in daily 1.8-Gy fractions. Results: The mean follow-up was 21.6 months after diagnosis and 14.6 months after RT. The response rate was 67.1%. The overall survival rate at 2 and 5 years was 30.5% and 9%, respectively, from the time of diagnosis (median survival time 16 months) and 19.9% and 4.7%, respectively, after RT (median survival time 10 months). On univariate analysis, tumor size (p = 0.047), the presence of portal vein thrombosis (p = 0.007), and RT dose (p = 0.001) were significant factors for survival. However, on multivariate analysis, RT dose was the only significant factor (p = 0.01). Conclusion: Local RT achieved substantial tumor regression and survival. The radiation dose was found to be a significant prognostic factor in the RT of hepatocellular carcinoma. Additional efforts for dose escalation are warranted to improve the treatment results in parallel with better protecting the nontumorous liver. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [31] Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: Retrospective study
    Yamashita, Hideomi
    Nakagawa, Keiichi
    Shiraishi, Kenshiro
    Tago, Masao
    Igaki, Hiroshi
    Nakamura, Naoki
    Sasano, Nakashi
    Siina, Shuichiro
    Omata, Masao
    Ohtomo, Kuni
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (04) : 523 - 527
  • [32] Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
    Lin, AY
    Brophy, N
    Fisher, GA
    So, S
    Biggs, C
    Yock, TI
    Levitt, L
    CANCER, 2005, 103 (01) : 119 - 125
  • [33] Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Morishita, Asahiro
    Okamoto, Koichi
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Masaki, Tsutomu
    Takayama, Tetsuji
    CANCERS, 2023, 15 (21)
  • [34] Ultrasound Patterns of Hepatocellular Carcinoma and Their Prognostic Impact: A Retrospective Study
    Barteselli, Chiara
    Mazza, Stefano
    Ravetta, Valentina
    Viera, Francesca Torello
    Veronese, Letizia
    Frigerio, Chiara
    Gori, Giulia
    Bergamaschi, Gaetano
    Sgarlata, Carmelo
    Facciorusso, Antonio
    Maestri, Marcello
    Di Sabatino, Antonio
    Anderloni, Andrea
    CANCERS, 2023, 15 (22)
  • [35] Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization
    Seong, J
    Park, HC
    Han, KH
    Lee, DY
    Lee, JT
    Chon, CY
    Moon, YM
    Suh, CO
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05): : 1331 - 1335
  • [36] Effects of stereotactic body radiotherapy for clinical outcomes of patients with liver metastasis and hepatocellular carcinoma: A retrospective study
    Liu, Canyu
    Yi, Qiong
    Zhou, Xuerong
    Han, Xu
    Jiang, Rui
    ONCOLOGY LETTERS, 2023, 26 (01)
  • [37] Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
    Brunner, Thomas B.
    Bettinger, Dominik
    Schultheiss, Michael
    Maruschke, Lars
    Sturm, Lukas
    Bartl, Nico
    Koundurdjieva, Ivana
    Kirste, Simon
    Neeff, Hannes P.
    Goetz, Christian
    Nicolay, Nils Henrik
    Ihorst, Gabriele
    Bamberg, Fabian
    Thimme, Robert
    Grosu, Anca-Ligia
    Gkika, Eleni
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Efficacy and factors related to prognosis of combination chemotherapy with different radiotherapy methods in patients with unresectable hepatocellular carcinoma
    Lian-Qiang Han
    Scientific Reports, 15 (1)
  • [39] Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery
    Zeng, Zhen-Xin
    Wu, Jia-Yi
    Wu, Jun-Yi
    Zhang, Zhi-Bo
    Wang, Kai
    Zhuang, Shao-Wu
    Li, Bin
    Zhou, Jian-Yin
    Lin, Zhong-Tai
    Li, Shu-Qun
    Li, Yi-Nan
    Fu, Yang-Kai
    Yan, Mao-Lin
    LIVER CANCER, 2024, 13 (05) : 498 - 508
  • [40] Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results
    Bae, Sun Hyun
    Jang, Won Il
    Park, Hee Chul
    ONCOTARGET, 2017, 8 (35) : 59965 - 59976